Electromed, Inc. Form 10-Q Summary
Reporting period: Three and nine months ended March 31, 2015, representing the third quarter and first nine months of fiscal 2015. The request identifies “2014 Q3,” but the filing reports March 31, 2015 results.
Business Context
Electromed develops, manufactures and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation therapy. Products are sold through U.S. home-care and institutional channels and internationally through direct sales and distributors. The company launched the next-generation SmartVest SQL in the domestic home-care market during the second half of fiscal 2014.
Financial Highlights
| Metric | Three Months Ended March 31 | Nine Months Ended March 31 |
|---|---|---|
| Net revenue | $4.557 million, up 15.2% | $14.209 million, up 30.6% |
| Gross profit | $3.157 million; 69.3% margin | $9.855 million; 69.4% margin |
| Operating income (loss) | $57,584 | $902,953 |
| Net income (loss) | $37,229 versus $(1.004) million | $837,469 versus $(1.579) million |
| Net income (loss) per diluted share | $0.00 versus $(0.12) | $0.10 versus $(0.19) |
| Net cash provided by operations | Not separately provided | $1.831 million versus $1.020 million |
Revenue growth was led by home-care revenue, which increased 18.5% to approximately $3.825 million in the quarter and 35.0% to approximately $12.133 million for the nine-month period. Government and institutional revenue increased 29.8% in the quarter and 13.3% year to date. International revenue declined 44.3% in the quarter to approximately $161,000 but increased 2.4% year to date to approximately $599,000.
SG&A expense increased 14.7% in the quarter to $3.021 million and 7.6% year to date to $8.715 million. Research and development expense declined 24.3% in the quarter and 41.5% year to date, reflecting completion of SmartVest SQL development and testing. Interest expense was approximately $20,000 for the quarter and $65,000 year to date.
Cash increased to $2.905 million at March 31, 2015 from $1.503 million at June 30, 2014. Working capital was approximately $10.0 million. Capital expenditures were $380,000 year to date, compared with $626,000 in the prior-year period. Financing cash outflows were approximately $49,000, principally debt principal payments and deferred financing fees.
Total debt was approximately $1.263 million at March 31, 2015, including $48,098 classified as current. The company had no balance outstanding on its $2.5 million revolving line of credit. The term loan had an outstanding principal balance of approximately $1.251 million, bears interest at 5.0%, and has a final payment due December 18, 2018.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased $601,000, or 15.2%, primarily from higher domestic home-care sales.
- Quarterly gross margin improved to 69.3% from 63.7%; year-to-date margin improved to 69.4% from 68.0%.
- The company returned to profitability, reporting quarterly net income of $37,229 and nine-month net income of $837,469, compared with losses in the prior-year periods.
- The prior-year periods included significant income-tax expense related primarily to recording a full valuation allowance against U.S. deferred tax assets. No income-tax expense was recorded in the current-year periods because net operating loss carryforwards offset taxable income.
- International quarterly revenue declined because European Union distributors pulled purchases forward before RoHS 2 compliance was achieved. The company stated that SmartVest SQL became compliant during the quarter and shipments to European Union distributors resumed.
- SG&A increased due to commissions, bonuses, information-technology and consulting costs, recruiting, and the medical-device excise tax. R&D declined following completion of SmartVest SQL development.
Outlook, Risks and Unusual Items
- Management expects to offer SmartVest SQL to institutional customers and selected international markets during the fourth quarter of fiscal 2015.
- The company plans to expand its sales team in densely populated U.S. regions. Management expects near-term sales-force costs to be offset by longer-term productivity improvements.
- Management expects R&D spending of approximately 2.0% to 4.0% of revenue over at least the next twelve months.
- SmartVest SQL manufacturing-cost initiatives resulted in tooling impairment charges of approximately $70,000 in the quarter and $177,000 year to date. Management expects approximately $43,000 of additional charges from current cost-reduction projects.
- Management believes gross margins can return to historical levels above 70% as sales grow and manufacturing costs are leveraged more effectively.
- The revolving credit line expires December 18, 2015. Management expects to renew it or obtain alternative financing but states that financing on favorable terms, or at all, cannot be guaranteed.
- The credit facility requires minimum tangible net worth of $10.125 million and restricts certain additional indebtedness and dividends. The company reported compliance at March 31, 2015. A covenant breach could permit acceleration of debt, restrict further borrowing, or prevent renewal of the line.
- Key business risks include reimbursement changes involving Medicare, Medicaid and private insurers; health-care and medical-device regulation; competition; international expansion; sales-force execution; intellectual-property claims; litigation; credit-market conditions; and general economic conditions.
- The company reported no material undisclosed litigation, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2015.
Investor Verification Items
- Verify the sustainability of home-care revenue growth, reimbursement-cycle improvements, referral-to-approval rates and higher average selling prices.
- Assess whether SmartVest SQL manufacturing costs decline as planned and whether gross margins recover above 70% after the remaining tooling charges.
- Monitor the December 18, 2015 revolving-credit renewal and continued compliance with the tangible-net-worth covenant.
- Review the realizability of net operating loss carryforwards and the continued full valuation allowance against deferred tax assets.
- Evaluate the effect of sales-force expansion, recruiting costs, commissions and bonuses on future operating leverage.
- Track international and institutional demand, including the timing of distributor purchases and resumed European Union shipments.